SCHEMBL5312141

SCHEMBL5312141

COc1cc(Nc2nc(C)nc3cc(Br)sc23)cc(N(C)C)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 1/20 0.35
EGFR P00533 4/20 0.34
KDR P35968 2/20 0.34
PDGFRB P09619 1/20 0.34
CLK1 P49759 2/20 0.34
DYRK1A Q13627 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
KDM1A O60341 3/20 0.32
FLT1 P17948 1/20 0.32
EPAS1 Q99814 1/20 0.32
IGF1R P08069 1/20 0.31
LCK P06239 1/20 0.31
CSNK2A1 P68400 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
RCE1 Q9Y256 1/20 0.31
PIK3CA P42336 1/20 0.31
APP P05067 1/20 0.31
GLA P06280 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5336835 0.90 DYRK1A (0.39) FBP1EGFRKDRPDGFRBCLK1
SCHEMBL5335568 0.83 EGFR (0.46) EGFRCLK1DYRK1ADYRK1BFLT1
SCHEMBL5314126 0.81 CSNK2A1 (0.39) EGFRKDRPDGFRBDYRK1ADYRK1B
SCHEMBL5332352 0.71 CLK1 (0.40) EGFRKDRPDGFRBCLK1DYRK1A
SCHEMBL5334233 0.71 EGFR (0.53) EGFRKDRCLK1DYRK1ADYRK1B
SCHEMBL5455366 0.69 CSNK2A1 (0.46) EGFRKDRPDGFRBCLK1DYRK1A
SCHEMBL5312123 0.66 EGFR (0.49) EGFRCLK1DYRK1ADYRK1BFLT1
SCHEMBL5371558 0.65 CLK1 (0.47) EGFRKDRCLK1DYRK1ADYRK1B
Hydrochloric Acid SCHEMBL5334353 0.65 EGFR (0.48) EGFRCLK1DYRK1ADYRK1BFLT1
SCHEMBL5480155 0.63 RAB9A (0.48) MEN1KMT2AAPPGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-05-03 US claimed
WO-2007056215-A9 N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF CYTOVIA INC (US) 2007-09-13 WO disclosed
WO-2007056215-A2 N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF CYTOVIA, INC. (US) 2007-05-18 WO disclosed
WO-2007056215-A2 N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF CYTOVIA, INC. (US) 2007-05-18 WO disclosed
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-05-03 US disclosed
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-05-03 US disclosed
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP4, CASP3, API5 FBP1 4716/4885EGFR 1226/4885KDR 1574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.